Gemfibrozil Tablet
Product Images NDC 50090-7809

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gemfibrozil (NDC 50090-7809). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Additional Adverse Reactions (Additional Adv Drug Reactions)

A tabular listing categorizing adverse reactions for GEMFIBROZIL tablets. The table separates reactions into two columns: 'Causal Relationship Probable' and 'Causal Relationship Not Established,' detailing various symptoms and conditions affecting different body systems including cardiac, gastrointestinal, central nervous, eye, genitourinary, musculoskeletal, clinical laboratory, hematopoietic, immunologic, and integumentary.*

FDA Label Image

Adverse Reactions (Adv Reactions)

Data table showing frequency percentages of adverse events in subjects treated with Gemfibrozil 600 mg tablets compared to placebo. It lists gastrointestinal reactions and other adverse events reported in more than 1% of subjects, highlighting differences in occurrence between Gemfibrozil and placebo groups.*

FDA Label Image

Struct (Structure Gemfibrozil)

Chemical structure of gemfibrozil, showing a benzene ring with two methyl groups, an ether linkage to a hydrocarbon chain, and a carboxylic acid functional group.*

FDA Label Image

Table1 (Table 1)

Table showing reduction in coronary heart disease (CHD) event rates per 1000 patients over 5 years in the Helsinki Heart Study, comparing placebo and gemfibrozil groups across different baseline lipid level categories. Events include fatal and nonfatal myocardial infarctions plus sudden cardiac deaths.*

FDA Label Image

Table2 (Table 2)

A data table titled 'Table II' presenting cardiac events and all-cause mortality rates (events per 1000 patients) during a 3.5-year open-label follow-up in the Helsinki Heart Study. It compares six groups with sample sizes and corresponding events and mortality rates, differentiated by drug and placebo statuses.*

FDA Label Image

Table3 (Table 3)

A data table titled 'Cardiac Events, Cardiac Deaths, Non-Cardiac Deaths, and All-Cause Mortality in the Helsinki Heart Study, Years 0-8.5.' It compares the number of events between Gemfibrozil and placebo groups at study start, and shows hazard ratios with confidence intervals for Gemfibrozil versus placebo for cardiac events, cardiac deaths, non-cardiac deaths, and all-cause mortality. Footnotes clarify study design and statistical measures.*

FDA Label Image

Label Image (Lbl500907809)

GEMFIBROZIL 600 mg oral tablets label by A-S Medication Solutions. The label specifies each tablet contains 600 mg of gemfibrozil. It includes storage instructions to keep at 68 to 77 degrees Fahrenheit, protect from light and humidity. The package contains 90 tablets, with NDC 50090-7809.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.